The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Gilead Sciences; Johnson & Johnson
Honoraria - Astellas Pharma; Bayer; Dendreon; Myriad Pharmaceuticals
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon
Research Funding - Amgen; Astellas Pharma; Bavarian Nordic; Janssen; Lilly; Millennium; Pfizer
 
Speakers' Bureau - Amgen; Celgene; Spectrum Pharmaceuticals
Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Sanofi (Inst); Sotio (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Ivor John Percent
No Relationships to Disclose
 
Sunil Babu
Employment - Fort Wayne Medical Oncology & Hematology
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology; Lutheran hospital (I)
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly
Consulting or Advisory Role - Alexion Pharmaceuticals; Bristol-Myers Squibb
Speakers' Bureau - Alexion Pharmaceuticals
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HERON (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Seagen (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Bristol-Myers Squibb; Lilly
 
Jennifer Cultrera
No Relationships to Disclose
 
Bryan Allyn Mehlhaff
Employment - Oregon Urology Institute
Honoraria - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer
Research Funding - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer
 
Oscar B. Goodman
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb
Consulting or Advisory Role - Exelixis
 
David Morris
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Janssen Oncology; Myriad Genetics; Pacific Edge Biotechnology; Urogen pharma; UROGPO
Research Funding - Merck (Inst); Taris BioMedical (Inst)
 
Ian D. Schnadig
Employment - Compass Oncology
Leadership - Compass Oncology
 
Costantine Albany
Stock and Other Ownership Interests - Advaxis
Honoraria - Sanofi
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Sanofi
 
Neal D. Shore
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Paul R Sieber
No Relationships to Disclose
 
Susan Guba
Employment - Lilly
 
Minmin Wang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Suhyun Kang
Travel, Accommodations, Expenses - Lilly
 
Volker Wacheck
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patent (Inst)
 
Gregory P Donoho
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Anna M. Szpurka
Employment - Lilly; Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly; Lilly (I)
Research Funding - Lilly; Lilly (I)
 
Sophie Callies
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Boris K. Lin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Rgenix (Inst); Sanofi (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical